Focus on Diabetes Care

Back to articles

Select antidiabetic medications associated with better mortality outcomes in patients with type 2 diabetes

KEY POINT

Use of sodium–glucose cotransporter 2 (SGLT-2) inhibitors and glucagon-like peptide 1 (GLP-1) agonists were both associated with significantly lower all-cause mortality and cardiovascular (CV) mortality compared with dipeptidyl peptidase 4 (DPP-4) inhibitors and placebo/no treatment in patients with type 2 diabetes, according to results of a systematic review and network meta-analysis published in JAMA.